From big bio­phar­ma to biotech CEO, John Hous­ton’s R&D jour­ney high­lights a fast-chang­ing world

John Hous­ton spent close to 30 years in the ranks of two big bio­phar­ma R&D or­ga­ni­za­tions. There was a decade at GSK fol­lowed by 18 more years at Bris­tol-My­ers Squibb, where he built a re­sume around con­struct­ing their drug dis­cov­ery tech­nol­o­gy base and was cred­it­ed with a key role in de­vel­op­ing a range of ma­jor fran­chise drugs like Op­di­vo and Yer­voy.

Then about two years ago, in­stead of de­vel­op­ing new drugs, he was charged with lend­ing a hand at shut­ting down two big re­search sites in Seat­tle and Walling­ford, CT, while BMS set its sights on a new R&D cen­ter in Cam­bridge.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.